Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-04T01:05:08.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-19T17:21:21.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T07:40:28.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update to v2.16.1. Additionally, specific studies related to Nivolumab and Ipilimumab have been removed.
    Difference
    3%
    Check dated 2025-05-29T04:55:50.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:43:56.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new version of the clinical trial study, with significant changes in the study's focus and eligibility criteria for participants. The previous version's detailed description of the study's purpose and drug combinations has been largely removed.
    Difference
    48%
    Check dated 2025-04-16T01:21:55.000Z thumbnail image

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.